Market Cap$12.02B
P/E16.00x
PEG Ratio0.46
Div yield—
Beta0.87
DVA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)15.43%
Price vs S&P 500 (4W)4.05%
PEG Ratio0.46
VGM Score55.47
P/E Ratio (Annual)16.00x
DVA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.88 | $4.02 | +3.55%(+$0.14) | |
| Q1 2026 | $2.33 | $2.87 | +23.18%(+$0.54) | |
| Q4 2025 | $3.19 | $3.40 | +6.51%(+$0.21) | |
| Q3 2025 | $3.17 | $2.51 | -20.90%(-$0.66) | |
| Q2 2025 | $2.75 | $2.95 | +7.32%(+$0.20) |
DVA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.50
3.46
3.46
3.54
Industry Peers — Health Services(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
DVADaVita Inc. | B | C | B | 16.0x | 6.5% | 15.1% | 181.2% | $187.31 |
| FMSFresenius Medical Care AG | A | D | C | 10.7x | -0.5% | 9.4% | 7.2% | $22.17 |
| SHCSotera Health Company Common Stock | D | B | C | 65.5x | 8.2% | 32.6% | 26.8% | $17.89 |
| PGNYProgyny, Inc. Common Stock | C | B | C | 35.2x | 5.5% | 8.6% | 16.0% | $26.86 |
| AGLagilon health, inc. | B | B | B | — | 0.3% | -5.2% | -110.3% | $85.12 |
| MCTACharming Medical Limited Class A Ordinary Shares | F | F | A | 371.6x | — | 15.4% | — | $29.36 |
| VMDViemed Healthcare, Inc. Common Shares | B | C | C | 24.2x | 25.2% | 7.5% | 10.3% | $9.48 |
| PARKPark Dental Partners, Inc. Common Stock | B | F | C | 17.9x | — | -2.8% | -18.3% | $18.95 |
| CCELCryo-Cell International Inc. | C | D | B | 69.5x | -2.0% | 0.6% | 38.2% | $4.42 |
| MGRXMangoceuticals, Inc. Common Stock | D | F | F | — | -38.9% | -4761.2% | -106.1% | $0.29 |
| BRTXBioRestorative Therapies, Inc. Common Stock (NV) | — | D | F | — | -8.5% | -3975.0% | -423.8% | $1.54 |
About DaVita Inc.
DaVita is the largest U.S. dialysis provider, operating over 3,000 facilities globally and treating approximately 280,000 patients annually, with roughly 35% of U.S. market share. The company derives about two-thirds of U.S. sales from government payers (primarily Medicare) at regulated reimbursement rates. Though commercial insurers represent only 10% of U.S. patients served, they generate nearly all profits from the U.S. dialysis business, creating significant earnings sensitivity to commercial payer mix.